There exists in the soil of the United States, Northern Mexico, and Central and South America the fungus Coccidioides immitis which in many specified regions produces an epidemic of continuing duration.
The fungus is well adapted to survive and indeed to grow in arid areas. In these areas dust storms arise very frequently and quite spontaneously. Many researchers have isolated Coccidioides immitis from soil samples, and the fungus killed mice. Seventy per cent of the Yaqui Indians in an area of Northern Mexico are dermally reactive to spherulin, a reagent analogous to tuberculin, and this indicates that they had had experience with Coccidioides immitis (Levine et al. 1973) .
Fortunately in most instances the experience is either asymptomatic or associated with a 'flulike syndrome (Fiese 1958) . Forty per cent of individuals experience some distress, bul period varying from months to several yt majority will recover. In 8 % of the cases coccidioidomycosis may develop, leading instances to death. COCCIDIOIDOMYCOSIS ENDEMIC AREAS
Fig 1 Geographical areas ofendemic coccidioidomycosis
Dr H B Levine t after a Translated into figures for the United States, ears, the we have annually approximately 85 000 new chronic conversions to coccidioidin, indicating an inin some fectious experience with this fungus. This means roughly 8000 cases requiring hospitalization or medical attention over a prolonged period of time. The only treatment drug in the last twentyfive years has been amphotericin B which is shunned by many until the disease is far advanced because of its nephrotoxicity (Rhoades et al. 1967 ). However, this situation changed a year ago. The fungus does not affect all people in quite the same manner. Among the so-called Caucasians (i.e. among people of European ancestry) the infection is managed quite well. Only 0.082 % of these people experience disseminated illness from pulmonary tissue to other parts of the body. However, among Filipinos the dissemination ratio is unparalleled, 14% or 14 000 per 100 000 LA (Fiese 1958) . The condition is also more common among Blacks and among Mexicans than it is in Caucasians. And these people who are most susceptible to coccidioidomycosis in its severest form are the very groups forced by our socioeconomic conditions to work close to the soil. We indeed have a problem of considerable proportions.
The primacy of the lung as a portal of entry is unquestioned. And though there can of course, be infections through the skin, this seldon happens.
The known areas of coccidioidal endemicity in the world are shown in Extrapolating the 85 000 annual experiences in the United States to include all the Americas, we estimate well over 125 000 new annual coccidioidal experiences in the New World. The fungus does not occur outside the New World. There have been reports of its occurrence in the Soviet Union, Romania and Czechoslovakia, but these reports are unconfirmed.
Amphotericin B is restricted in its usefulness. We therefore sought to explore the potential efficacy of miconazole and the results literally shocked us. In mice, intranasally infected to produce pulmonary disease with dissemination to the liver, in conditions where 100 % of untreated animals die, 100% of miconazole-treated animals survive and survive indefinitely (Levine et al. 1975) . We have carried out this experiment to over 77 days. The dose of drug was given intramuscularly or subcutaneously. This is not a recommended route, but in animals treated intravenously, the tail vein collapses. Since treatment is twice daily, we were forced to use the intramuscular or the subcutaneous route. The optimal dose we now believe is 2.2 mg per mouse or 70 mg/kg twice daily and this is undoubtedly life-saving.
The effect of the drug is to reduce fungal multiplication. In control animals by day 11 there were approximately 108 organisms per lung or lung lobe. In the treated animal there are 10, -a hundred times fewer (Levine et al. 1975 ). Thus the drug restricts multiplication of Coccidioides immitis, in vivo.
After 77 days the animals are not cleared in conditions where treatment was discontinued at 30 days. The surviving untreated animals, the immune or refractory, have the same numbers of organisms in the lungs, but the treated group have fewer in the liver and considerably fewer in the spleen. These animals live out their normal days although they remain infected.
A single dose of miconazole nitrate intramuscularly produces higher plasma levels than a comparable oral dose (Fig 2) . I have recently learned that thv free base can be given orally, but, in all our studies in animals and later in man the parenteral route was used, intramuscularly in animals, intravenously in man. Fig 3 shows an aspect of coccidioidal infections which is relevant to assays of drug activity. On the left are the saprophytic forms, the mycelium and the arthrospores. These saprophytic forms which grow on non-living media in the soil are not as susceptible to miconazole as the parasitic forms. Fortuitously, the spherule and its endospore, the forms of this dimorphic fungus that are found predominantly in host tissue, are susceptible.
In vivo the spherule form ruptures to release copious quantities of endospores which are associated with metastatic lesions.
With considerable difficulty the endospore form can be produced in vitro. Only these forms should be used to assay the sensitivity of Coccidioides immitis to miconazole.
The top dose-response relationships of Fig 4 , plotted on a logarithmic scale, show the exquisite susceptibility of coccidioidal endospores to miconazole. The mycelial form, shown by the multiplicity of other lines, is considerably more resistant. It is most unfortunate that there is no relationship between the degree of resistance or susceptibility of the mycelial form and the degree of susceptibility of the endospore. Since it may take many weeks, or even months, to convert a strain to the form which can be assessed for sensitivity, treatment in cases of amphotericin failure must begin prior to having this information. I have worked closely with David Stevens, who has by now treated approximately 23 patients (Stevens et al. 1976) . Table 1 gives the data on the 14 patients who were treated very thoroughly. All 14 were failures on existing therapy. They could not or would not take more amphotericin B. There was objective evidence of improvement in 8 of them and subjective evidence of improvement in most in that most said they felt better. When these men arrived, some of them were moribund and comatose. There was failure in one and in three patients there were equivocal results, although they said that they felt better. Other workers have reported comparable findings in the efficacy of miconazole (Sung 1976 ).
Thus we feel that for the first time in a quarter of a century there is an alternative drug that can be used in the treatment of deep coccidioidomycosis.
Summary
The epidemiology of Coccidioides immitis is described with respect to annual infection rates and differing ethnic susceptibilities to the infection. A trial of miconazole in infected mice produced 100% survival in conditions which normally kill 100% of animals, probably by drastically reducing the rate of fungal multiplication in the lung. The fungal endospore, the form of the dimorphic fungus found predominantly in host tissue is more sensitive to miconazole than is the mycelial form.
Data are presented from 14 human patients, some moribund and comatose, all of whom had failed to respond to existing therapy. There was objective evidence of improvement in eight, and a subjective impression of improvement ih the majority. One patient failed to respond and three have equivocal results.
Systemic Mycoses

DISCUSSION
Professor Vanbreuseghem (Chairman) said that Dr Levine had dedicated his life to the study of Coccidioides immitis and had considerably improved our techniques for obtaining spherules and producing antigens from them which are quite different from the ones obtained from the mycelial phase.
Dr A M R Mackenzie (Southampton) congratulated Dr Levine. It was a great pleasure to hear such beautifully presented work. He wished to pursue a question raised by Professor Van- breuseghem, namely the differential susceptibility of the mycelial as opposed to the spherule form. Since Dr Levine agreed that mycelial forms may occur in natural infections, Dr Mackenzie asked if this implied that there was a possibility of chemotherapeutic breakdown, and whether this problem had been investigated. Dr Levine said that it had been investigated indirectly. The predominant structures were the spherule and endospore and in the majority of instances these were virtually the only structures. In some cases however there were mycelia and they too were susceptible, although approximately ten times less so. Ideally of course, the drug would effect both forms equally. However, in his experience in animals and that of Dr Stevens and Dr Sung in man, the effect was such as to reduce the numbers of fungi so that the host survived. In some cases, those patients who had been anergic, with the lessened fungal load, recovered dermal sensitivity and were able to cope immunologically more successfully with the fungus. Miconazole produced fungistasis in the mycelium but this form was not so sensitive as the endospores and spherules.
Dr L J R Milne (Edinburgh) asked in what chronological order, in Dr Levine's animal system, the inoculum and the treatment were given. Dr Levine replied that the animals were infected intranasally on Day 1. The infecting dose consisted of arthrospores, which were the exclusive infectious structure of Coccidioides immitis.
These were instilled intranasally into anisthetized animals. The dose was usually of the magnitude of 50 spores per animal. No treatment was initiated until Day 5. By Day 5 the pulmonary load in the lungs was of the order of 103 to 104 fungal particles per lung. Therapy initiated on Day 5 was continued until Day 19 or 20, twice daily with 100% survival in a situation which killed virtually all of the controls. More recently they had discontinued therapy at Day 12 and still got 100% survival at an intramuscular dose of 140 mg/kg twice daily.
Dr M Buckout (Leiden) asked what Dr Levine's treatment scheme now was, and whether he still chose amphotericin as the drug of first choice in the treatment of coccidioides. Secondly, what was his incidence of treatment failures with amphotericin and when he used miconazole on his patients, what dosage did he use. Dr Levine said the drug of choice at present by law is amphotericin B. Only recently had the use of miconazole been permitted under the Investigational New Drug status. The full data were not yet available. With both drugs therapy must be prolonged, since after a period of months following the discontinuation of therapy there could be exacerbation or recrudescence of illness.
The doses varied per patient. A thrice daily dose of 500 mg intravenously had been used in the studies shown. He believed that this had now been raised to about 900 mg but the studies were by Dr Stevensand he did not have the full details.
Professor E Drouhet (Paris) asked whether the same differences between the yeast and mycelial phase had been seen for other dimorphic fungi such as histoplasma or sporotrichum. Dr Levine said he could not answer that question. He had worked only with Histoplasma capsulatum. The yeast form was somewhat more susceptible but the number of treated histoplasma patients with whom he had been associated was only three. One was a failure. However, the strain of histoplasma was so aberrant that even the National Centre for Disease could not at first identify it properly. The remaining two patients seemed to have been treated quite successfully although he did not have the full details.
He had nothing further to add on dimorphic fungi except that he had been told that in the University of Minnesota miconazole was the drug of choice in pulmonary and meningeal cryptococcosis.
